AU2008292859C1 - Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity - Google Patents

Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity Download PDF

Info

Publication number
AU2008292859C1
AU2008292859C1 AU2008292859A AU2008292859A AU2008292859C1 AU 2008292859 C1 AU2008292859 C1 AU 2008292859C1 AU 2008292859 A AU2008292859 A AU 2008292859A AU 2008292859 A AU2008292859 A AU 2008292859A AU 2008292859 C1 AU2008292859 C1 AU 2008292859C1
Authority
AU
Australia
Prior art keywords
compound
mhz
mmol
nmr
cdcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008292859A
Other languages
English (en)
Other versions
AU2008292859B2 (en
AU2008292859A1 (en
Inventor
Yih-Shyun Edmond Cheng
Jim-Min Fang
Jia-Tsrong Jan
Jiun-Jie Shie
Chi-Huey Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of AU2008292859A1 publication Critical patent/AU2008292859A1/en
Application granted granted Critical
Publication of AU2008292859B2 publication Critical patent/AU2008292859B2/en
Publication of AU2008292859C1 publication Critical patent/AU2008292859C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU2008292859A 2007-08-31 2008-08-29 Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity Ceased AU2008292859C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96949107P 2007-08-31 2007-08-31
US60/969,491 2007-08-31
US4850708P 2008-04-28 2008-04-28
US61/048,507 2008-04-28
PCT/US2008/074914 WO2009029888A2 (en) 2007-08-31 2008-08-29 Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity

Publications (3)

Publication Number Publication Date
AU2008292859A1 AU2008292859A1 (en) 2009-03-05
AU2008292859B2 AU2008292859B2 (en) 2013-09-19
AU2008292859C1 true AU2008292859C1 (en) 2014-03-06

Family

ID=40388153

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008292859A Ceased AU2008292859C1 (en) 2007-08-31 2008-08-29 Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity

Country Status (8)

Country Link
US (1) US7888337B2 (enExample)
EP (1) EP2190439B1 (enExample)
JP (1) JP5509080B2 (enExample)
KR (1) KR101535691B1 (enExample)
CN (1) CN101883569B (enExample)
AU (1) AU2008292859C1 (enExample)
CA (1) CA2697837C (enExample)
WO (1) WO2009029888A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
DK2318832T3 (da) 2008-07-15 2014-01-20 Academia Sinica Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
BRPI1010981A2 (pt) 2009-05-15 2018-12-04 Redx Pharma Ltd "derivados de fármaco redox"
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
DK2568976T3 (en) * 2010-05-10 2016-01-11 Academia Sinica Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
US8515882B2 (en) 2010-11-18 2013-08-20 International Business Machines Corporation Efficient storage of individuals for optimization simulation
US8489526B2 (en) 2010-11-24 2013-07-16 International Business Machines Corporation Controlling quarantining and biasing in cataclysms for optimization simulations
US9563844B2 (en) 2011-06-30 2017-02-07 International Business Machines Corporation Speculative asynchronous sub-population evolutionary computing utilizing a termination speculation threshold
KR101331167B1 (ko) * 2011-08-26 2013-11-19 주식회사 씨트리 신규한 오셀타미비르 유도체 및 그 제조방법
DE102011117128A1 (de) * 2011-10-28 2013-05-02 Christian-Albrechts-Universität Zu Kiel Verbindungen zur Therapie der Influenza
US9165247B2 (en) 2012-01-04 2015-10-20 International Business Machines Corporation Using global and local catastrophes across sub-populations in parallel evolutionary computing
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CN103848762B (zh) * 2012-11-30 2016-08-31 北京普禄德医药科技有限公司 神经氨酸苷酶抑制剂的前药及其组合物和用途
RU2521593C1 (ru) * 2013-02-27 2014-06-27 Общество с ограниченной ответственностью "Интеллектуальный Диалог" Моно и дифторзамещенные этил (3r,4r,5s)-5-азидо-4-ацетиламино-3-(1-этилпропокси)-циклогексен-1-карбоксилаты, способ получения и применения
US9305257B2 (en) 2013-05-20 2016-04-05 International Business Machines Corporation Adaptive cataclysms in genetic algorithms
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
EP3041484B1 (en) 2013-09-06 2021-03-03 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
JP2017518989A (ja) 2014-05-27 2017-07-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃｄ２０糖操作抗体群およびその使用
EP4116329A1 (en) 2014-05-27 2023-01-11 Academia Sinica Anti-her2 glycoantibodies and uses thereof
KR20170010003A (ko) 2014-05-27 2017-01-25 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
CN114315626A (zh) * 2021-12-21 2022-04-12 艾希尔（深圳）药物研发有限公司 一种奥司他韦脱烷基杂质的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026933A1 (en) * 1995-02-27 1996-09-06 Gilead Sciences, Inc. Novel selective inhibitors of viral or bacterial neuraminidases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282950B6 (sk) * 1990-04-24 2003-01-09 Biota Scientific Management Pty Ltd Deriváty alfa-D-neuramínovej kyseliny, spôsob ich prípravy, ich použitie a farmaceutické prípravky na ich báze
WO1992006691A1 (en) 1990-10-19 1992-04-30 Biota Scientific Management Pty. Ltd. Anti-viral compounds that bind the active site of influenza neuramidase and display in vivo activity against orthomyxovirus and paramyxovirus
US5763483A (en) 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
US20080009639A1 (en) 2006-07-10 2008-01-10 Apotex Pharmachem Inc. Preparation of oseltamivir phosphate (Tamiflu) and intermediates starting from D-glucose or D-xylose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026933A1 (en) * 1995-02-27 1996-09-06 Gilead Sciences, Inc. Novel selective inhibitors of viral or bacterial neuraminidases

Also Published As

Publication number Publication date
US20100113397A1 (en) 2010-05-06
US7888337B2 (en) 2011-02-15
CN101883569A (zh) 2010-11-10
EP2190439B1 (en) 2016-03-09
WO2009029888A2 (en) 2009-03-05
WO2009029888A3 (en) 2009-05-07
AU2008292859B2 (en) 2013-09-19
EP2190439A4 (en) 2013-02-20
CA2697837A1 (en) 2009-03-05
JP2010538019A (ja) 2010-12-09
KR101535691B1 (ko) 2015-07-09
JP5509080B2 (ja) 2014-06-04
CA2697837C (en) 2016-08-16
AU2008292859A1 (en) 2009-03-05
KR20100074156A (ko) 2010-07-01
EP2190439A2 (en) 2010-06-02
CN101883569B (zh) 2013-08-21

Similar Documents

Publication Publication Date Title
AU2008292859B2 (en) Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity
CA2835489C (en) Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
TWI659963B (zh) 經取代核苷、核苷酸及其類似物
AU2016229147B2 (en) Aza-pyridone compounds and uses thereof
PT759917E (pt) Novos inibidores selectivos de neuraminidases virais ou bacterianas
WO1992006691A1 (en) Anti-viral compounds that bind the active site of influenza neuramidase and display in vivo activity against orthomyxovirus and paramyxovirus
WO2015038660A1 (en) Pyridazinone compounds and uses thereof
US20120010254A1 (en) Compounds and methods for treatment of influenza
EP2125848B1 (en) Antiviral compounds
US9284292B2 (en) Sialochimeric compounds
KR20060127906A (ko) 4'-치환된 카보버와 아바카비어 유도체 및 ｈｉｖ와 ｈｃｖ항바이러스 활성을 갖는 관련 화합물
NZ520724A (en) Tetrahydro-pyridine compounds for inhibiting neuraminidase and treating influenza neuraminidase
US8883846B2 (en) Synthesis of bicyclic compounds and method for their use as therapeutic agents
Ma Carbohydrate-derived molecular diversity: synthesis and application in cell biology

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 NOV 2013 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 NOV 2013

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired